search
Back to results

Non-Pharmacologic Alternatives for Childhood Obesity

Primary Purpose

Obesity in Childhood

Status
Completed
Phase
Not Applicable
Locations
Mexico
Study Type
Interventional
Intervention
Agave inulin
Curcumin
O3FA
Control
Sponsored by
Coordinación de Investigación en Salud, Mexico
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity in Childhood focused on measuring Children, obesity, agave-inulin, curcumin, O3FA

Eligibility Criteria

6 Years - 8 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Gender: Boys and Girls
  • Diagnosis of obesity (percentile ≥ 95% according to The Centers for Disease Control and Prevention growth charts)
  • Informed consent of parents
  • Informed assent of the participant

Exclusion criteria:

  • Diabetes
  • Thyroid disease
  • Renal disease
  • Hepatic disease
  • Neoplasia disease
  • Chronic gastrointestinal conditions
  • Consume of prebiotics or probiotics
  • Consume of prebiotics or food supplements
  • Use of anti-inflammatory drugs.
  • Recent use of antibiotics (30 days)

Sites / Locations

  • Biomedical Research Unit. IMSS. Durango

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Other

Arm Label

Agave inulin

Curcumin

Omega 3 Fatty Acids

Control

Arm Description

Agave inulin 2.3 g, by mouth, every 12 hours for 3 months. Plus recommendations to decrease calories intake an do exercise.

Curcumin 600 mg (turmeric 600 + black pepper 5 mg) by mouth, daily for 3 months. Plus recommendations to decrease calories intake an do exercise.

O3FA 600 mg (eicosapentaenoic acid 360; docosahexaenoic acid 240) Three times a day by mouth, every 8 hours for 3 months. Plus recommendations to decrease calories intake an do exercise.

Recommendations to decrease calories intake an do exercise.

Outcomes

Primary Outcome Measures

Loosing weight
Weight lost between basal and third month visits. Determined by a digital scale

Secondary Outcome Measures

Full Information

First Posted
September 12, 2018
Last Updated
September 27, 2023
Sponsor
Coordinación de Investigación en Salud, Mexico
search

1. Study Identification

Unique Protocol Identification Number
NCT03670875
Brief Title
Non-Pharmacologic Alternatives for Childhood Obesity
Official Title
Non-Pharmacologic Alternatives for the Treatment of Childhood Obesity in Mexico
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
July 31, 2021 (Actual)
Primary Completion Date
October 31, 2022 (Actual)
Study Completion Date
December 30, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Coordinación de Investigación en Salud, Mexico

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Childhood obesity is a global health issue. Mexico has been considered as the country with the higher number of children with obesity. There are not approved drugs to support diet and exercise as the first step to lose weight. Animal models and clinical trials in adults have provided evidence about safety and efficacy of interventions such as: prebiotics, curcumin, and omega- 3 fatty acids. The hypothesis of this study is: that non-pharmacological alternatives could support diet and exercise to decrease the weight of children with obesity.
Detailed Description
The aim of this study is to determinate the efficacy and safety of agave inulin, curcumin, and omega-3 fatty acids (O3FA) to decrease the weight of children with obesity. Design. Randomized controlled clinical trial (RCT) with four study groups: agave inulin, curcumin, omega-3 fatty acids and a control group. All groups will receive instructions to decrease calories intake and do exercise. Children sent to the unit with a presumptive diagnosis of obesity will be considered as candidates to the RCT. Children accomplishing with inclusion/exclusion criteria will be randomized to one of the study groups. Sample size was calculated using a statistical power of 80%, alpha value of 0.05. A 15 % of difference, in the mean of weight reduction, between control group and intervention groups was considered. The estimated sample size was 75 subjects for each group. Weight, height, BMI, blood pressure, abdominal circumference and body fat percentage will be measured in months 0, 1, 2, and 3. In months 0 and 3 a fasting venous blood sample will be drawn to perform the following test: glucose, insulin, lipid profile and C- Reactive protein, aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Anthropometric measures, food intake recommendation and diaries of food consume will be performed by trained nutritionists. Recommendation about type of exercise and estimation of calories consumed will be performed by a physical education teacher. The statistical analysis will performed by one to the investigators blinded to treatment groups. Numerical values will be expressed as mean ± standard deviation. Categorical variables will be expressed as proportions. The analysis will be preformed according with CONSORT group recommendations Differences between the groups were estimated using one-way ANOVA with Bonferroni post-hoc test for numerical parameters and χ 2 test for categorical variables. Intragroup differences will be assessed by paired Student t test (Mann-Whitney U test for skewed data). Statistical significance will be considered as a p value <0.05 and 95% confidence interval (CI). Statistical Package for the Social Sciences will be used for the analysis

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity in Childhood
Keywords
Children, obesity, agave-inulin, curcumin, O3FA

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Study groups. Agave inulin: 2.3 g twice a day by mouth during 3 months plus recommendations to decrease calories intake an do exercise. Curcumin: 600 mg (turmeric 600 + black pepper 5 mg) by mouth daily during 3 months plus recommendations to decrease calories intake an do exercise. Omega-3 fatty acids 600 mg (eicosapentaenoic acid 360; docosahexaenoic acid 240) Three times a day by mouth during 3 months plus recommendations to decrease calories intake an do exercise. Control group with no intervention. Recommendations to decrease calories intake an do exercise. Dietary recommendations to ingest 1600 calories per day Exercise: 30 minutes each day, al least 5 days a week (caloric consumption 150-200 kcal per day)
Masking
None (Open Label)
Allocation
Randomized
Enrollment
300 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Agave inulin
Arm Type
Experimental
Arm Description
Agave inulin 2.3 g, by mouth, every 12 hours for 3 months. Plus recommendations to decrease calories intake an do exercise.
Arm Title
Curcumin
Arm Type
Experimental
Arm Description
Curcumin 600 mg (turmeric 600 + black pepper 5 mg) by mouth, daily for 3 months. Plus recommendations to decrease calories intake an do exercise.
Arm Title
Omega 3 Fatty Acids
Arm Type
Experimental
Arm Description
O3FA 600 mg (eicosapentaenoic acid 360; docosahexaenoic acid 240) Three times a day by mouth, every 8 hours for 3 months. Plus recommendations to decrease calories intake an do exercise.
Arm Title
Control
Arm Type
Other
Arm Description
Recommendations to decrease calories intake an do exercise.
Intervention Type
Dietary Supplement
Intervention Name(s)
Agave inulin
Intervention Description
Will be provided in dehydrated apple cubes
Intervention Type
Dietary Supplement
Intervention Name(s)
Curcumin
Other Intervention Name(s)
Turmeric
Intervention Description
Will be provided in capsules
Intervention Type
Dietary Supplement
Intervention Name(s)
O3FA
Intervention Description
Will be provided in capsules
Intervention Type
Behavioral
Intervention Name(s)
Control
Intervention Description
Dietary recommendations to ingest 1600 calories per day. Exercise: 30 minutes each day, al least 5 days a week (caloric consumption 150-200 kcal per day)
Primary Outcome Measure Information:
Title
Loosing weight
Description
Weight lost between basal and third month visits. Determined by a digital scale
Time Frame
Three months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
8 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Gender: Boys and Girls Diagnosis of obesity (percentile ≥ 95% according to The Centers for Disease Control and Prevention growth charts) Informed consent of parents Informed assent of the participant Exclusion criteria: Diabetes Thyroid disease Renal disease Hepatic disease Neoplasia disease Chronic gastrointestinal conditions Consume of prebiotics or probiotics Consume of prebiotics or food supplements Use of anti-inflammatory drugs. Recent use of antibiotics (30 days)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fernando Guerrero, PhD
Organizational Affiliation
Instituto Mexicano del Seguro Social
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Gerardo Martinez, PhD
Organizational Affiliation
Instituto Mexicano del Seguro Social
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Luis E Simental, PhD
Organizational Affiliation
Instituto Mexicano del Seguro Social
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Claudia I Gamboa, PhD
Organizational Affiliation
Instituto Mexicano del Seguro Social
Official's Role
Study Chair
Facility Information:
Facility Name
Biomedical Research Unit. IMSS. Durango
City
Durango
State/Province
Dgo
ZIP/Postal Code
34067
Country
Mexico

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
25797547
Citation
Gluckman P, Nishtar S, Armstrong T. Ending childhood obesity: a multidimensional challenge. Lancet. 2015 Mar 21;385(9973):1048-50. doi: 10.1016/S0140-6736(15)60509-8. No abstract available.
Results Reference
background
PubMed Identifier
18582508
Citation
Siro I, Kapolna E, Kapolna B, Lugasi A. Functional food. Product development, marketing and consumer acceptance--a review. Appetite. 2008 Nov;51(3):456-67. doi: 10.1016/j.appet.2008.05.060. Epub 2008 Jun 4.
Results Reference
background
PubMed Identifier
23811098
Citation
Tomaschunas M, Zorb R, Fischer J, Kohn E, Hinrichs J, Busch-Stockfisch M. Changes in sensory properties and consumer acceptance of reduced fat pork Lyon-style and liver sausages containing inulin and citrus fiber as fat replacers. Meat Sci. 2013 Nov;95(3):629-40. doi: 10.1016/j.meatsci.2013.06.002. Epub 2013 Jun 10.
Results Reference
background
PubMed Identifier
17002459
Citation
Mancilla-Margalli NA, Lopez MG. Water-soluble carbohydrates and fructan structure patterns from Agave and Dasylirion species. J Agric Food Chem. 2006 Oct 4;54(20):7832-9. doi: 10.1021/jf060354v.
Results Reference
background
Citation
González-Herrera SM, Rutiaga-Quiñones OM, Aguilar CN, et al. Dehydrated Apple matrix supplemented with agave fructans, inulin and oligofructose. LWT Food Science and Technology. 2016;65:1059-1065.
Results Reference
background
PubMed Identifier
24687355
Citation
Lopez-Velazquez G, Diaz-Garcia L, Anzo A, Parra-Ortiz M, Llamosas-Gallardo B, Ortiz-Hernandez AA, Mancilla-Ramirez J, Cruz-Rubio JM, Gutierrez-Castrellon P. Safety of a dual potential prebiotic system from Mexican agave "Metlin(R) and Metlos(R)", incorporated to an infant formula for term newborn babies: a randomized controlled trial. Rev Invest Clin. 2013 Nov-Dec;65(6):483-90.
Results Reference
background
PubMed Identifier
19462685
Citation
Wang SL, Li Y, Wen Y, Chen YF, Na LX, Li ST, Sun CH. Curcumin, a potential inhibitor of up-regulation of TNF-alpha and IL-6 induced by palmitate in 3T3-L1 adipocytes through NF-kappaB and JNK pathway. Biomed Environ Sci. 2009 Feb;22(1):32-9. doi: 10.1016/S0895-3988(09)60019-2.
Results Reference
background
PubMed Identifier
23239418
Citation
Sahebkar A. Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? Biofactors. 2013 Mar-Apr;39(2):197-208. doi: 10.1002/biof.1062. Epub 2012 Dec 13. Erratum In: Biofactors. 2013 Sep-Oct;39(5):591.
Results Reference
background
PubMed Identifier
11040400
Citation
Ramirez-Bosca A, Soler A, Carrion MA, Diaz-Alperi J, Bernd A, Quintanilla C, Quintanilla Almagro E, Miquel J. An hydroalcoholic extract of curcuma longa lowers the apo B/apo A ratio. Implications for atherogenesis prevention. Mech Ageing Dev. 2000 Oct 20;119(1-2):41-7. doi: 10.1016/s0047-6374(00)00169-x.
Results Reference
background
Citation
Nagwa I, Ragab S, Baky A, et al. Effect of Oral Curcumin Administration on Insulin Resistance, Serum Resistin and Fetuin-A in Obese Children: Randomized Placebo- Controlled study. Reser J of Pharm, Biol and Chem Sci 2014 5:887-96
Results Reference
background
PubMed Identifier
23059643
Citation
Suskind DL, Wahbeh G, Burpee T, Cohen M, Christie D, Weber W. Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study. J Pediatr Gastroenterol Nutr. 2013 Mar;56(3):277-9. doi: 10.1097/MPG.0b013e318276977d.
Results Reference
background
PubMed Identifier
14686961
Citation
Huang XF, Xin X, McLennan P, Storlien L. Role of fat amount and type in ameliorating diet-induced obesity: insights at the level of hypothalamic arcuate nucleus leptin receptor, neuropeptide Y and pro-opiomelanocortin mRNA expression. Diabetes Obes Metab. 2004 Jan;6(1):35-44. doi: 10.1111/j.1463-1326.2004.00312.x.
Results Reference
background
PubMed Identifier
15481762
Citation
Couet C, Delarue J, Ritz P, Antoine JM, Lamisse F. Effect of dietary fish oil on body fat mass and basal fat oxidation in healthy adults. Int J Obes Relat Metab Disord. 1997 Aug;21(8):637-43. doi: 10.1038/sj.ijo.0800451.
Results Reference
background
PubMed Identifier
23438101
Citation
Juarez-Lopez C, Klunder-Klunder M, Madrigal-Azcarate A, Flores-Huerta S. Omega-3 polyunsaturated fatty acids reduce insulin resistance and triglycerides in obese children and adolescents. Pediatr Diabetes. 2013 Aug;14(5):377-83. doi: 10.1111/pedi.12024. Epub 2013 Feb 25.
Results Reference
background
PubMed Identifier
18602429
Citation
Parra D, Ramel A, Bandarra N, Kiely M, Martinez JA, Thorsdottir I. A diet rich in long chain omega-3 fatty acids modulates satiety in overweight and obese volunteers during weight loss. Appetite. 2008 Nov;51(3):676-80. doi: 10.1016/j.appet.2008.06.003. Epub 2008 Jun 14.
Results Reference
background

Learn more about this trial

Non-Pharmacologic Alternatives for Childhood Obesity

We'll reach out to this number within 24 hrs